At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3,002 enrolled
Drug / intervention
Rapamycin + Probucol-eluting stent (ISAR stent) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis
In Brief
A Phase 4 clinical trial evaluating Rapamycin + Probucol-eluting stent (ISAR stent) and polymer based Zotarolimus-eluting stent (Endeavor Resolute) for Coronary Heart Disease. Completed, enrolled 3,002 participants across 2 sites.
Detailed Summary
The purpose of this trial is to evaluate the efficacy of Rapamycin- and Zotarolimus-Eluting stents for the reduction of Coronary Restenosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartFeb 2008
Primary CompletionAug 2010
Study CompletionSep 2010
TodayJul 2026
First PostedJan 22, 2008
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2010
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 18.4 years ago
Interventions
Rapamycin + Probucol-eluting stent (ISAR stent)device
due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
polymer based Zotarolimus-eluting stent (Endeavor Resolute)device
due to randomization, Zotarolimus-eluting stent with polymer will be implanted